-+ 0.00%
-+ 0.00%
-+ 0.00%

Betta Pharmaceuticals announced that the marketing license application for ensartinib hydrochloride capsules declared by Xdiscovery, a holding subsidiary of the company, was approved by the European Commission. The marketing license number EU/1/26/2078 is used for the treatment of adult patients with advanced anaplastic lymphoma kinase positive advanced non-small cell lung cancer. Ensatinib became the first domestically produced ALK inhibitor approved for marketing in China, the US, and the European Union.

Zhitongcaijing·11/18/2026 08:01:04
Listen to the news
Betta Pharmaceuticals announced that the marketing license application for ensartinib hydrochloride capsules declared by Xdiscovery, a holding subsidiary of the company, was approved by the European Commission. The marketing license number EU/1/26/2078 is used for the treatment of adult patients with advanced anaplastic lymphoma kinase positive advanced non-small cell lung cancer. Ensatinib became the first domestically produced ALK inhibitor approved for marketing in China, the US, and the European Union.